Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; titanium dioxide; macrogol 6000; hypromellose; macrogol 400; magnesium stearate; povidone; lactose monohydrate - early breast cancer adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. advanced breast cancer first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease.. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease.. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg - tablet, uncoated - excipient ingredients: amylopectin; potato starch; lactose monohydrate; magnesium stearate - short-term treatment of menopausal syndrome. review the need for continuation of treatment after 6 months treatment, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, refer to clinical trials and precautions). ovestin tablets should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: silicon dioxide; crospovidone; hypromellose; magnesium carbonate hydrate; mannitol; microcrystalline cellulose; methyl hydroxybenzoate; macrogol 6000; polysorbate 80; polyvinyl alcohol; sodium starch glycollate; sucrose; titanium dioxide; cetyl esters wax; purified talc; carnauba wax; shellac; iron oxide black; magnesium stearate; purified water; sorbic acid; dimeticone 100; dimeticonol; benzoic acid - aromasin is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,aromasin is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised potato starch; ascorbyl palmitate; magnesium stearate; lactose monohydrate; lactose - ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women. ? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, <> (tibolone tablets) should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, see clinical trials and precautions). <> (tibolone tablets) should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.